Reset filter
Mots-clés
Non Small Cell Lung Cancer ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
    1. 1.1. Inclusion/exclusion
    1. 1.2. Anamnèse
    1. 1.3. Examen médical
    1. 1.4. Score
    1. 1.5. Diagnostic à l’aide d’appareils
    1. 1.6. Laboratoire
    1. 1.7. Pathologie/histologie
    1. 1.8. Informations/consentement
    1. 1.9. Thérapie
    1. 1.10. Rapport opératoire
    1. 1.11. Évènement inopportun
    1. 1.12. Follow-Up
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

411 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Baseline Local Laboratory Data, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Baseline Local Laboratory Data, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 01/04/2022 - 1 Formulaire, 3 Groupes Item, 18 Eléments de données, 1 Langue
Groupes Item: Hematology, Biochemistry, Pregnancy Tests
Sponsor: OSI Pharmaceuticals Information provided by : Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Baseline Local Laboratory Data

Eligibility Carcinoma, Non-Small-Cell Lung NCT00001499

- 17/11/2021 - 1 Formulaire, 1 Groupe Item, 20 Eléments de données, 1 Langue
Groupe Item: Criteria
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00001499

Eligibility Non-Small Cell Lung Cancer NCT02515435

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 22 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02515435

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT02409342

- 27/09/2021 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 110]; ODM derived from: https://clinicaltrials.gov/show/NCT02409342

Eligibility Non Small Cell Lung Cancer NCT01017874

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01017874

Eligibility Non Small Cell Lung Cancer NCT01020786

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01020786

Eligibility Non Small Cell Lung Cancer NCT00988858

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study of Advanced or Metastatic Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00988858

Eligibility Non-Small Cell Lung Cancer NCT00886678

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801); ODM derived from: https://clinicaltrials.gov/show/NCT00886678

Eligibility Non-Small-Cell Lung Cancer NCT00705549

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 20 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00705549

Eligibility Non-Small-Cell Lung Cancer NCT00550173

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00550173

Eligibility Non-small Cell Lung Cancer NCT00994097

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 27 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00994097

Eligibility Carcinoma, Non-Small-Cell Lung NCT02411591

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 19 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT02411591

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial